About: Placental barrier against COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Placental barrier against COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Placental barrier against COVID-19
Creator	Hayakawa, Satoshi Komine-Aizawa, Shihoko Takada, Kazuhide
Source	Elsevier; Medline; PMC
abstract	Vertical transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and possible induction of pregnancy complications, including miscarriage, fetal malformations, fetal growth restriction and/or stillbirth, are serious concerns for pregnant individuals with COVID-19. According to clinical information, the incidence of vertical transmission of SARS-CoV-2 is limited to date. However, even if a neonate tests negative for SARS-CoV-2, frequent abnormal findings, including fetal and maternal vascular malperfusion, have been reported in cases of COVID-19-positive mothers. Primary receptor of SARS-CoV-2 is estimated as angiotensin-converting enzyme 2 (ACE2). It is highly expressed in maternal-fetal interface cells, such as syncytiotrophoblasts, cytotrophoblasts, endothelial cells, and the vascular smooth muscle cells of primary and secondary villi. However other route of transplacental infection cannot be ruled out. Pathological examinations have demonstrated that syncytiotrophoblasts are often infected with SARS-CoV-2, but fetuses are not always infected. These findings suggest the presence of a placental barrier, even if it is not completely effective. As the frequency and molecular mechanisms of intrauterine vertical transmission of SARS-CoV-2 have not been determined to date, intensive clinical examinations by repeated ultrasound and fetal heart rate monitoring are strongly recommended for pregnant women infected with COVID-19. In addition, careful investigation of placental samples after delivery by both morphological and molecular methods is also strongly recommended.
has issue date	2020-07-25(xsd:dateTime)
bibo:doi	10.1016/j.placenta.2020.07.022
bibo:pmid	32755724
has license	no-cc
sha1sum (hex)	179caff456452f918863b90601342746b6bde9de
schema:url	https://doi.org/10.1016/j.placenta.2020.07.022
resource representing a document's title	Placental barrier against COVID-19
has PubMed Central identifier	PMC7381919
has PubMed identifier	32755724
schema:publication	Placenta
resource representing a document's body	covid:179caff456452f918863b90601342746b6bde9de#body_text
is schema:about of	named entity 'incidence' named entity 'ACE2' named entity 'abnormal' named entity 'smooth muscle cells' named entity 'SARS-CoV-2' named entity 'fetal heart rate' named entity 'completely' named entity 'primary' named entity 'Journal' named entity 'FETAL GROWTH RESTRICTION' named entity 'POSITIVE' named entity 'INTRAUTERINE' named entity 'TRANSPLACENTAL INFECTION' named entity 'VASCULAR SMOOTH MUSCLE' named entity 'fetal' named entity 'malformations' named entity 'angiotensin-converting enzyme 2' named entity 'placental barrier' named entity 'syncytiotrophoblasts' named entity 'negative' named entity 'ACE2' named entity 'receptor' named entity 'ultrasound' named entity 'vascular smooth muscle cells' named entity 'infection' named entity 'vertical transmission' named entity 'SARS-CoV-2' named entity 'lung' named entity 'congenital' named entity 'ACE2' named entity 'intrauterine fetal demise' named entity 'SARS-CoV-2' named entity 'ACE2' named entity 'cell membrane' named entity 'ACE2' named entity 'vertical transmission' named entity 'rubella' named entity 'vaginal fluid' named entity 'placenta' named entity 'vertical transmission' named entity 'ACE2' named entity 'trophoblast' named entity 'pathophysiological' named entity 'fetal' named entity 'mRNA expression' named entity 'infarction' named entity 'villous' named entity 'trophoblast' named entity 'clinical data' named entity 'spike protein' named entity 'spontaneous abortion' named entity 'GDM' named entity 'infection' named entity 'fetal malformations' named entity 'angiotensin' named entity 'ACE2' named entity 'COVID' named entity 'angiotensin' named entity 'macrophages' named entity 'SARS-CoV-2' named entity 'angiotensin' named entity 'vaccines' named entity 'angiotensin' named entity 'SARS-CoV-2' named entity 'fibrin' named entity 'karyorrhexis' named entity 'endothelial cells' named entity 'SARS-CoV-2' named entity 'chronic inflammatory' named entity 'staining' named entity 'endothelium' named entity 'smooth muscles' named entity 'pyroptosis' named entity 'stillbirth' named entity 'COVID' named entity 'Vertical transmission' named entity 'infection' named entity 'villous' named entity 'fetal'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software